Log in

Pfizer rides Paxlovid sales growth to better-than-expected third quarter

By TOM MURPHY
Posted 10/29/24

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the year. Demand for the drugmaker’s Paxlovid treatment spurred by the …

This item is available in full to subscribers.

Please log in to continue

Log in


X
X